Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 23 February, 2021

Cellular Goods PLC

£13 million raised in Initial Public Offering

RNS Number : 0363Q
Cellular Goods PLC
23 February 2021
 

Press Release

23 February 2021

NOT FOR PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES OR AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA, OR ANY PROVINCE OR TERRITORY THEREOF OR TO OR FOR THE ACCOUNT OF ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES OR ANY PERSON RESIDENT IN AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA.

 

 Cellular Goods PLC

("Cellular Goods" or "the Company")

 

£13 million raised in Initial Public Offering

Over 6,000 small investors to receive share allocations

Publication of prospectus

 

Cellular Goods, a UK-based provider of premium consumer products based on biosynthetic cannabinoids, is pleased to announce that it has attracted strong demand from institutional and private investors for its initial public offering to join the main market of the London Stock Exchange (LSE).

The Company has raised gross proceeds of £13 million from a conditional placing and an intermediaries offer which was 13 times oversubscribed.

Cellular Goods will be valued at a market capitalisation of £25 million at launch, and it will be the first pure-play biosynthetic cannabinoids consumer products company to list on the LSE.

The Company will have a total of 504,750,000 shares in issue upon its expected admission. Tennyson Securities and Novum Securities are acting as joint bookrunners and brokers to the Company. PrimaryBid is acting as retail adviser.

A total of 260 million ordinary shares, representing 51.5% of the Company's issued capital on admission, are being issued at an offer price of 5p a share, of which 192 million shares have been conditionally placed with institutional investors and 68 million have been allocated to ordinary investors through PrimaryBid.

More than 6,000 valid applications were received under the retail offer, resulting in a significant oversubscription. As a result, the Company has scaled down allocations to accommodate as many small investors as possible in a fair manner. Accordingly:

· Any retail subscription, up to the first £500, has been allocated in full, and

· Any retail subscription greater than £500 has been given an allocation of 2.85% of the additional amount above £500, up to a maximum total allocation of £2,500

PrimaryBid will refund any unused portions of their clients' subscription monies before the end of the month.

Net proceeds from the IPO will be used to fund the development of Cellular Goods' cannabinoids-based business and to enable it to finalise the development of, and launch, its initial product range for cosmetics and sports recovery.

Alexis Abraham, Chief Executive Officer, said: "We are delighted with the tremendous support we have received from institutional capital and the unprecedented level of interest shown by retail investors for an IPO of this size.

"We want to involve as many private investors as possible so that they can both be part of and benefit from our growth as we become the trusted brand in consumer cannabinoids. Technology now means that 'listening at scale' is not just a possibility but a requirement for successful consumer brands. We firmly believe that the future of the cannabinoid industry will be driven by biosynthetic production and our significantly oversubscribed IPO is a sign of investor confidence in this future. "

The Company's shares are expected to commence trading under the ticker symbol CBX from 8am on Friday 26 February 2021, subject to the approval of its application for admission to the standard listing segment of the LSE. The prospectus, which has been approved by the Financial Conduct Authority, is available at www.cellulargoods.co .

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Cellular Goods 

 

Alexis Abraham

Chief Executive

 

 

Neil Thapar

Investor Relations

+44 207 031 6871

 

 

 

+44 787 645 5323

Tennyson Securities

 

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

 

+44 207 399 9427  

 

PrimaryBid

 

Retail Adviser

James Deal

 

Mike Coombes 

 

+44 203 026 4750

 

 

 

Tancredi Intelligent Communication

Media Relations

 

Helen Humphrey

Edward Daly

Salamander Davoudi

[email protected]

 

+44 744 922 6720

+44 795 429 2488

+44 795 754 9906

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PDISEDFSDEFSESE

a d v e r t i s e m e n t